Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UVax 2129

Drug Profile

UVax 2129

Alternative Names: 1c-SApNP vaccine - Ufovax; Coronavirus vaccine - Ufovax; UVax-2129

Latest Information Update: 04 Dec 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Scripps Research Institute
  • Developer The Scripps Research Institute; Uvax Bio
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 11 Nov 2021 Scripps Research has patents pending for the 1C-SApNP platform technology and individual vaccines in USA (UVax Bio website, November 2021)
  • 03 Nov 2021 Immunogenicity data from preclinical studies in COVID-2019 infections (Prevention) released by UVax Bio
  • 03 Nov 2021 Preliminary immunogenicity data from research studies in COVID-2019 infections (Prevention) released by UVax Bio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top